10-Q: Spruce Biosciences Faces Going Concern Doubt, Nasdaq Delisting

Spruce Biosciences reports substantial doubt about its ability to continue as a going concern, alongside a Nasdaq delisting and significant workforce reduction, despite positive clinical data for TA-ERT.

Summary

• Incurred a net loss of $16.1 million for the six months ended June 30, 2025, and used $21.6 million of cash in operations during the same period.
• Accumulated deficit reached $266.4 million as of June 30, 2025, with cash and cash equivalents of $16.4 million, deemed insufficient to fund planned operations for at least 12 months.
• Common stock was delisted from Nasdaq on April 29, 2025, and began trading on the OTCQB under SPRB, followed by a one-for-seventy-five (1:75) reverse stock split effective August 7, 2025, trading under SPRBD.
• Implemented a 55% workforce reduction on April 21, 2025, to prioritize the development of tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B.
• Clinical studies for TA-ERT (201, 202, 401) demonstrated a significant reduction in cerebral spinal fluid heparan-sulfate non-reducing end (CSF HS-NRE) levels (91.5 ng/mL decrease from baseline, p<0.0001) and stabilization of cognitive function over five years in MPS IIIB patients.
• The FDA confirmed CSF-HS-NRE as a biomarker reasonably likely to predict clinical benefit, potentially supporting accelerated approval for TA-ERT, with a Biologics License Application (BLA) submission planned for Q1 2026.
• Initiated a Phase 2 proof-of-concept clinical trial (TAMARIND) for tildacerfont in Major Depressive Disorder (MDD) patients, with topline results anticipated in H1 2026.
• Discontinued the tildacerfont congenital adrenal hyperplasia (CAH) development program due to failure to meet primary efficacy endpoints in the CAHmelia-203 and CAHmelia-204 trials.
• Acquired intellectual property and inventory related to Allievex's product candidates for $5.0 million in November 2024, with an initial aggregate net acquisition cost of $15.1 million, later reduced to $11.0 million due to changes in estimates.
• Entered into a collaboration and license agreement with HBM Alpha Therapeutics, Inc. in January 2025, involving an upfront payment of $5.0 million and the issuance of pre-funded warrants equal to 4.99% of outstanding common stock.
• Amended the Twist Antibody License Agreement in July 2025 to extend the exercise period for the Twist Option to December 2025.

Sentiment

Score: 2

Explanation: The company faces substantial doubt about its ability to continue as a going concern, has been delisted from Nasdaq, and implemented a significant workforce reduction. While there is promising clinical data for TA-ERT and plans for BLA submission, the severe financial distress and discontinuation of another key program (tildacerfont for CAH) overshadow these positives, indicating a very challenging operational and financial environment.

Positives

• Positive clinical data for TA-ERT in MPS IIIB, showing significant reduction in CSF HS-NRE levels (91.5 ng/mL decrease from baseline, p<0.0001) and stabilization of cognitive function over five years.
• The FDA confirmed CSF-HS-NRE as a biomarker reasonably likely to predict clinical benefit, potentially supporting accelerated approval for TA-ERT.
• Intends to submit a Biologics License Application (BLA) for TA-ERT for MPS IIIB in Q1 2026, indicating progress towards potential commercialization.
• Initiated a Phase 2 proof-of-concept clinical trial (TAMARIND) for tildacerfont in MDD, leveraging a companion diagnostic (Cortibon) for patient stratification.
• Acquisition of Allievex's product candidates and intellectual property, including TA-ERT, expands the company's pipeline and focus on rare neurological disorders.
• Workforce reduction aims to prioritize TA-ERT development, focusing resources on a promising candidate.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern due to insufficient working capital.
• Common stock was delisted from Nasdaq Capital Market on April 29, 2025, and now trades on the OTCQB, which could reduce market liquidity and stock price.
• Reported a significant net loss of $16.1 million for the six months ended June 30, 2025.
• Experienced negative cash flow from operations, using $21.6 million for the six months ended June 30, 2025.
• Accumulated deficit of $266.4 million as of June 30, 2025, highlights a history of unprofitability.
• Discontinuation of the tildacerfont CAH development program due to failure to meet primary efficacy endpoints in two Phase 2b trials (CAHmelia-203 and CAHmelia-204).
• A 55% workforce reduction indicates severe financial constraints and operational restructuring.
• The prior sponsor of TA-ERT, Allievex, discontinued clinical development due to financial constraints, highlighting potential challenges for the asset.
• The fair value of the warrant liability decreased by $619 thousand, potentially reflecting a decrease in the underlying stock price or volatility.

Risks

• Inability to regain compliance with Nasdaq requirements could adversely affect market liquidity and stock price.
• Insufficient working capital to fund planned operations for the next twelve months, raising substantial doubt about the ability to continue as a going concern.
• Need for substantial additional financing; failure to obtain it may force delays, reductions, or elimination of product development or commercialization efforts.
• Limited operating history and significant net losses since inception, with anticipated continued and increasing losses.
• Inability to advance product candidates in clinical development, obtain regulatory approval, or commercialize them, or significant delays in doing so.
• Clinical trials may fail to adequately demonstrate safety and efficacy, preventing or delaying regulatory approval.
• Significant competition from other biotechnology and pharmaceutical companies.
• Lengthy and expensive preclinical and clinical drug development process with uncertain outcomes; earlier results may not predict future trial results.
• Difficulties enrolling patients in clinical trials could delay or adversely affect development activities.
• Delays in commencement or completion, or termination/suspension, of clinical trials could increase costs, delay revenue generation, and adversely affect commercial prospects.
• TA-ERT and tildacerfont are subject to extensive, costly, and time-consuming regulation and compliance obligations, which may cause unanticipated delays or prevent required approvals.
• Interim, topline, and preliminary data from clinical trials may change, and are subject to audit and verification.
• Market opportunities for product candidates may be smaller than believed, adversely affecting future revenue.
• No current marketing and sales organization; inability to establish capabilities or third-party agreements could prevent product revenue generation.
• Unfavorable U.S. and global economic and geopolitical conditions could adversely affect business, financial condition, or results of operations.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business.
• High dependence on key personnel; failure to attract and retain qualified personnel could hinder business strategy.
• Coverage and reimbursement may be limited or unavailable, making profitable sales difficult.
• Failure to develop and commercialize additional product candidates may prevent business growth.
• Dependence on intellectual property licensed from others; termination could result in loss of significant rights.
• Reliance on third parties to conduct clinical trials; failure to carry out duties or meet deadlines could prevent regulatory approval or commercialization.
• Complete reliance on third parties to manufacture drug supplies; failure to obtain/maintain regulatory approval for facilities, provide sufficient quantities, or meet quality/price standards.
• Inability to obtain and maintain sufficient intellectual property protection, or insufficient scope of protection, could allow competitors to commercialize similar products.
• Use of TA-ERT, tildacerfont, or other product candidates could be associated with side effects or adverse events, delaying or preventing regulatory approval or leading to negative consequences post-approval.
• Ongoing regulatory obligations and review post-approval may result in significant additional expense and penalties for non-compliance.
• Changes in funding for FDA and other government agencies could hinder timely development/commercialization.
• Product candidates may not gain market acceptance among physicians, patients, and payors.
• Improper promotion of off-label uses or off-label prescription could lead to prohibitions, fines, or product liability claims.
• Coverage and reimbursement may be limited or unavailable, making profitable sales difficult.
• Current and future legislation and healthcare reform measures may increase difficulty and cost of obtaining marketing approval and commercializing products.
• Failure to obtain regulatory approval in international jurisdictions would prevent international marketing.
• Risks associated with marketing internationally could adversely affect business.
• Need to grow the size of the organization, which may present management difficulties.
• Indebtedness to Silicon Valley Bank may limit operational flexibility and is secured by substantially all assets (excluding IP); default could lead to foreclosure.
• Business disruptions (e.g., natural disasters, epidemics) could harm revenues and increase costs.
• Employees, contractors, etc., may engage in misconduct or improper activities, including noncompliance with regulatory standards.
• Relationships with customers, healthcare providers, and third-party payors may be subject to healthcare fraud and abuse laws, false claims laws, health information privacy and security laws.
• Information technology systems or data, or those of third parties, being compromised could lead to adverse consequences.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Subject to U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption, and anti-money laundering laws.
• Ability to utilize net operating loss carryforwards and other tax attributes may be limited.
• Changes in U.S. patent law could diminish the value of patents.
• Inability to protect intellectual property rights throughout the world.
• Claims challenging inventorship or ownership of patents and other intellectual property.
• Inability to obtain or maintain necessary rights to product components and processes through acquisitions and in-licenses.
• Third-party claims alleging intellectual property infringement may prevent or delay drug discovery and development.
• Issued patents could be found invalid or unenforceable.
• Inability to protect the confidentiality of trade secrets.
• Inadequate protection of trademarks and trade names.
• Collaboration arrangements may not be successful.

Future Outlook

The company anticipates continued significant net losses for the foreseeable future, expecting them to increase with clinical development and regulatory approvals for product candidates. Current cash and cash equivalents are deemed insufficient to fund planned operations and debt obligations for at least 12 months, indicating a critical need for additional financing. The company intends to submit a Biologics License Application (BLA) for TA-ERT for MPS IIIB in Q1 2026, seeking accelerated approval, and plans to initiate a confirmatory Phase 3 trial prior to potential accelerated approval. Topline results from the Phase 2 clinical trial (TAMARIND) for tildacerfont in MDD are anticipated in H1 2026. Expenses are expected to increase significantly due to ongoing development, commercialization efforts, manufacturing expansion, and intellectual property protection, necessitating substantial additional capital through various financing avenues.

Management Comments

• We have incurred significant losses and negative cash flows from operations.
• Without alternative financing or proceeds from other strategic alternatives, we believe that based on our current operating plan, our cash and cash equivalents of $16.4 million as of June 30, 2025 will be insufficient to fund our planned operations and debt obligations for at least 12 months following the issuance date of these financial statements.
• Accordingly, there is substantial doubt about our ability to continue as a going concern for at least 12 months following the issuance date of these financial statements.
• Our common stock will resume trading on the Nasdaq Capital Market so long as the Company remains in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for 20 consecutive trading days following the Effective Date, inclusive.
• We expect our expenses will increase significantly in connection with our ongoing activities.
• We do not expect to generate any meaningful revenue unless and until we obtain regulatory approval and commercialize TA-ERT or any other current or future product candidates, and we do not know when, or if at all, that will occur.
• We intend to submit the BLA for TA-ERT for the treatment of MPSIIIB in the first quarter of 2026.
• Topline results from TAMARIND are anticipated in the first half of 2026.

Industry Context

The biopharmaceutical industry is characterized by intense competition, rapid innovation, and a lengthy, expensive, and uncertain drug development process. The company's focus on rare neurological disorders like MPS IIIB highlights the challenges of limited patient populations for clinical trials and market size. The FDA's confirmation of CSF-HS-NRE as a biomarker for accelerated approval of TA-ERT aligns with regulatory efforts to expedite therapies for serious unmet medical needs. The use of companion diagnostics for patient stratification in MDD trials reflects a broader industry trend towards precision medicine. Global economic and geopolitical conditions, including inflation and international conflicts, are impacting operating costs, liquidity, and access to capital across the industry. Changes in healthcare reform measures and increased scrutiny on pharmaceutical pricing are creating an uncertain regulatory and reimbursement landscape.

Comparison to Industry Standards

• Many competitors have substantially greater financial, technical, and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces.
• Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies.
• Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in competitors.
• The biopharmaceutical industry is characterized by intense competition and rapid innovation.
• Only a small percentage of drugs in development successfully complete the FDA or foreign regulatory approval processes and are commercialized.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• May become involved in legal proceedings arising in the ordinary course of business.
• Could be subject to securities class action litigation following periods of stock price volatility.
• May be subject to claims challenging the inventorship or ownership of patents and other intellectual property.
• May face third-party claims alleging intellectual property infringement.
• Currently a party to an opposition proceeding with the European Patent Office and a Revocation Proceeding with respect to EP Patent No. 3,678,649.

Related Party Transactions

• On May 28, 2025, the company entered into a Purchase Agreement with Michael Grey, the Executive Chairman of the Board, to issue and sell one share of Series A Preferred Stock to him for $100.00.
• Kirk Ways, M.D., a member of the Board, began serving as the Company's interim Chief Medical Officer pursuant to a consulting agreement, with compensation expense of $0.3 million recognized during the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future capital raises, adverse impact on market liquidity and stock price due to Nasdaq delisting and reverse stock split, and substantial doubt about the company's ability to continue as a going concern, which could lead to loss of investment. No dividends are anticipated.
• Employees have been impacted by a 55% workforce reduction, indicating job losses and potential morale issues for remaining staff. Competition for skilled personnel remains intense.
• Patients may benefit from potential new therapies (TA-ERT for MPS IIIB, tildacerfont for MDD) if development is successful, but the discontinuation of tildacerfont for CAH means no further development for that indication.
• Creditors, particularly Silicon Valley Bank, hold obligations under a Term Loan secured by substantially all of the company's assets (excluding intellectual property), posing a risk of foreclosure in case of default.
• Suppliers and partners, including CROs and manufacturers, face potential disruptions if the company's financial instability or business operations are affected.

Next Steps

• Regain compliance with Nasdaq Capital Market minimum bid price requirement for 20 consecutive trading days to resume trading on Nasdaq.
• Raise additional capital through public or private equity offerings, license agreements, debt financings, or other strategic alternatives.
• Submit Biologics License Application (BLA) for TA-ERT for the treatment of MPS IIIB in Q1 2026.
• Initiate a confirmatory Phase 3 trial for TA-ERT (placebo-controlled 5-year study with a 2-year interim analysis in 14 patients) prior to potential accelerated approval.
• Advance TA-ERT through a planned confirmatory study in patients with MPSIIB and expanded access programs.
• Expand manufacturing capacity for TA-ERT.
• Advance clinical development of tildacerfont in Major Depressive Disorder (MDD) with topline results from TAMARIND anticipated in H1 2026.
• Advance preclinical and clinical development of SPR202 in congenital adrenal hyperplasia (CAH).
• Implement operational, financial, and management information systems.
• Hire additional personnel.
• Obtain, maintain, expand, and protect its intellectual property portfolio.
• Seek strategic collaborations for markets outside the United States.
• Nasdaq Hearings Panel will maintain jurisdiction until October 20, 2025, requiring advice on plans to cure any listing deficiency if non-compliant.
• Evaluate the impact of Accounting Standards Update 2024-03 on financial statements and disclosures.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on business and financial condition, to be reflected in the Form 10-K for the year ended December 31, 2025.

Key Dates

Recommendation

The company explicitly states 'substantial doubt about the Company's ability to continue as a going concern' and that its current cash is 'insufficient to fund its planned operations and debt obligations for at least 12 months.' This is a critical red flag for investors. The delisting from Nasdaq and subsequent trading on the OTCQB significantly reduces market liquidity and investor confidence, making the stock less attractive. A 55% workforce reduction and the discontinuation of a key development program (tildacerfont for CAH) underscore severe financial and operational challenges. While positive clinical data for TA-ERT and plans for BLA submission offer a glimmer of hope, the immediate and severe financial distress, coupled with the need for substantial additional financing in an uncertain economic environment, presents an extremely high-risk profile. The potential for significant dilution from future capital raises further diminishes the attractiveness for existing shareholders. Given the existential threat to the company's operations, a strong sell recommendation is warranted for risk-averse investors.

Keywords

Biopharmaceutical, MPS IIIB, Sanfilippo Syndrome Type B, TA-ERT, tildacerfont, Major Depressive Disorder, MDD, SPR202, Congenital Adrenal Hyperplasia, CAH, SEC filing, 10-Q, financial results, going concern, Nasdaq delisting, reverse stock split, clinical trials, drug development, intellectual property, regulatory approval, biotechnology, financial health, risk management, corporate governance, capital raise, pre-funded warrants, HBM Alpha Therapeutics, Twist Bioscience